



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

25 June 2026
EMADOC-1700519818-3191549
Committee for Medicinal Products for Human Use (CHMP)

Summary of opinion¹ (post authorisation)

MenQuadfi

Meningococcal Group A, C, W and Y conjugate vaccine

On 25 June 2026, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending a change to the terms of the marketing authorisation for the medicinal product MenQuadfi. The marketing authorisation holder for this medicinal product is Sanofi Winthrop Industrie.

The CHMP adopted an extension to the existing indication as follows:²

MenQuadfi is indicated for active immunisation of individuals from the age of **6 weeks** ~~12 months~~ and older against invasive meningococcal disease caused by *Neisseria meningitidis* serogroups A, C, W, and Y.

The use of this vaccine should be in accordance with available official recommendations.

Detailed recommendations for the use of this product will be described in the updated summary of product characteristics (SmPC), which will be published on the EMA website in all official European Union languages after a decision on this change to the marketing authorisation has been granted by the European Commission.

¹ Summary of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 days from adoption of the opinion.

² New text in bold, removed text as strikethrough.

